Total Payments
$22,953
2024 Payments
$4,036
Companies
81
Transactions
1,175
Medicare Patients
6,804
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$21,850 (95.2%)
Education$1,104 (4.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $21,850 | 1,152 | 95.2% |
| Education | $1,104 | 23 | 4.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,153 | 120 | $0 (2024) |
| Incyte Corporation | $1,501 | 53 | $0 (2024) |
| Celgene Corporation | $1,405 | 74 | $0 (2024) |
| Janssen Biotech, Inc. | $1,382 | 66 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,340 | 70 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,301 | 74 | $0 (2024) |
| PFIZER INC. | $1,252 | 88 | $0 (2024) |
| Astellas Pharma US Inc | $1,243 | 54 | $0 (2024) |
| Merck Sharp & Dohme LLC | $942.32 | 51 | $0 (2024) |
| GENZYME CORPORATION | $770.20 | 36 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,036 | 170 | AstraZeneca Pharmaceuticals LP ($368.20) |
| 2023 | $3,706 | 167 | Incyte Corporation ($315.94) |
| 2022 | $3,369 | 152 | Incyte Corporation ($434.85) |
| 2021 | $3,233 | 161 | Incyte Corporation ($436.62) |
| 2020 | $2,150 | 125 | Janssen Biotech, Inc. ($214.38) |
| 2019 | $2,273 | 136 | Novartis Pharmaceuticals Corporation ($360.67) |
| 2018 | $2,447 | 150 | Novartis Pharmaceuticals Corporation ($450.77) |
| 2017 | $1,739 | 114 | Novartis Pharmaceuticals Corporation ($326.07) |
All Payment Transactions
1,175 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $15.77 | General |
| 12/17/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $26.70 | General |
| Category: Hematology | ||||||
| 12/16/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $33.72 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.69 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: Oncology | ||||||
| 12/09/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $31.53 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $31.59 | General |
| Category: Hematology | ||||||
| 11/26/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/25/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug), Odomzo | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Oncology | ||||||
| 11/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Oncology | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $33.58 | General |
| Category: Oncology | ||||||
| 11/11/2024 | SEAGEN INC. | — | Education | In-kind items and services | $74.99 | General |
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.64 | General |
| 11/07/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Genetically Defined Disease | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,087 | 6,154 | $488,791 | $174,218 |
| 2022 | 18 | 1,552 | 8,993 | $869,206 | $266,976 |
| 2021 | 22 | 1,931 | 16,942 | $1.3M | $387,487 |
| 2020 | 19 | 2,234 | 12,544 | $1.2M | $364,162 |
Total Patients
6,804
Total Services
44,633
Medicare Billing
$1.2M
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 257 | 923 | $192,907 | $83,690 | 43.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 67 | 248 | $68,200 | $23,357 | 34.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 13 | 111 | $30,081 | $10,950 | 36.4% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 20 | 530 | $51,940 | $9,212 | 17.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 241 | 1,010 | $10,096 | $8,462 | 83.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 135 | $27,405 | $8,451 | 30.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 239 | 999 | $34,965 | $7,573 | 21.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 49 | 49 | $19,551 | $6,637 | 33.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 38 | 38 | $15,352 | $6,515 | 42.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 46 | $6,624 | $2,405 | 36.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 27 | 199 | $9,552 | $2,038 | 21.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,025 | $1,317 | 43.5% |
| 88189 | Flow cytometry technique for dna or cell analysis, 16 or more markers | Office | 2023 | 20 | 20 | $4,160 | $1,305 | 31.4% |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | Office | 2023 | 20 | 26 | $4,186 | $1,228 | 29.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 11 | 79 | $3,555 | $930.63 | 26.2% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 16 | 1,713 | $6,852 | $127.29 | 1.9% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 11 | 17 | $340.00 | $19.89 | 5.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 286 | 1,049 | $219,241 | $94,411 | 43.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 134 | 668 | $183,700 | $54,387 | 29.6% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2022 | 66 | 1,771 | $173,558 | $28,884 | 16.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 90 | 290 | $58,870 | $16,343 | 27.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 83 | 88 | $35,112 | $13,785 | 39.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 268 | 1,322 | $46,270 | $10,149 | 21.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 97 | $26,287 | $9,965 | 37.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $16,775 | $7,275 | 43.4% |
About Dr. Thomas Katta, MD
Dr. Thomas Katta, MD is a Hematology & Oncology healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205934288.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Katta, MD has received a total of $22,953 in payments from pharmaceutical and medical device companies, with $4,036 received in 2024. These payments were reported across 1,175 transactions from 81 companies. The most common payment nature is "Food and Beverage" ($21,850).
As a Medicare-enrolled provider, Katta has provided services to 6,804 Medicare beneficiaries, totaling 44,633 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Orlando, FL
- Active Since 09/21/2006
- Last Updated 01/26/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1205934288
Products in Payments
- JAKAFI (Drug) $1,197
- KEYTRUDA (Biological) $927.74
- OPDIVO (Biological) $797.25
- IMBRUVICA (Drug) $558.07
- XTANDI (Drug) $531.14
- ERLEADA (Drug) $531.02
- REBLOZYL (Biological) $487.39
- Revlimid (Drug) $451.14
- LIBTAYO (Biological) $403.41
- TASIGNA (Drug) $376.97
- XARELTO (Drug) $373.71
- XPOVIO (Drug) $352.39
- SARCLISA (Biological) $325.56
- Pomalyst (Drug) $322.70
- KISQALI (Drug) $320.20
- VERZENIO (Drug) $315.38
- Lenvima (Drug) $307.35
- BOSULIF (Drug) $305.49
- TUKYSA (Drug) $297.73
- MEKINIST (Drug) $280.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Orlando
Dr. Mark Socinski, Md, MD
Hematology & Oncology — Payments: $3.1M
Hematology & Oncology $3.1M
Tarek Mekhail, M.d, M.D
Hematology & Oncology — Payments: $2.7M
Hematology & Oncology $2.7M
Dr. Daniel Landau, Md, MD
Hematology & Oncology — Payments: $2.0M
Hematology & Oncology $2.0M
Sajeve Thomas, Md, MD
Hematology & Oncology — Payments: $843,415
Hematology & Oncology $843,415
Rebecca Moroose, Md, MD
Hematology & Oncology — Payments: $790,811
Hematology & Oncology $790,811
Dr. Nikita Shah, Md, MD
Hematology & Oncology — Payments: $493,804
Hematology & Oncology $493,804